摘要
由美国国家综合癌症网络(National Comprehensive Cancer Network,NCCN)牵头制定的2022年V1最新版《NCCN小细胞肺癌临床实践指南》(以下简称为《指南》)刚发布。该指南以高质量的循证医学证据为基础,为全球临床医师提供临床诊治参考,受到了广泛认可和肯定。相比于2021年V3版,《指南》有了较多重要信息的更新修订,主要集中于放疗和全身治疗进展。本文将对该新版《指南》更新内容进行解读。
The National Comprehensive Cancer Network(NCCN) released the latest version 1, 2022 of "NCCN guidelines for the clinical diagnosis and treatment of small cell lung cancer"(hereinafter referred to as "guideline"). Based on high-quality evidence-based medicine, this guideline provides references of clinical diagnosis and treatment for clinicians around the world. Compared with the version 3, 2021 of the "guideline", updates and revisions mainly focused on the progress of radiotherapy and systemic treatment. This article will interpret the updated therapy content in this new version of the "guideline".
作者
简政
张亚杰
张家豪
李鹤成
JIAN Zheng;ZHANG Yajie;ZHANG Jiahao;LI Hecheng(Department of Thoracic Surgery,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,200025,P.R.China)
出处
《中国胸心血管外科临床杂志》
CSCD
北大核心
2021年第11期1272-1276,共5页
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
基金
国家自然科学基金项目(81871882,81902951)
上海市卫生计生系统优秀学科带头人培养计划(2017BR055)
上海市教育委员会高峰高原学科建设计划(20172005)。
